Logo image of KIN

Kindred Biosciences (KIN) Stock Fundamental Analysis

USA - NASDAQ:KIN -

9.25
+0.01 (+0.11%)
Last: 8/27/2021, 8:19:13 PM
9.26
+0.01 (+0.11%)
After Hours: 8/27/2021, 8:19:13 PM
Fundamental Rating

2

Taking everything into account, KIN scores 2 out of 10 in our fundamental rating. KIN was compared to 534 industry peers in the Biotechnology industry. KIN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KIN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KIN has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -38.53%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -500.9%
PM (TTM) -529.26%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

KIN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 4.83 indicates that KIN is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 0.19 indicates that KIN is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 4.83
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 7.02 indicates that KIN has no problem at all paying its short term obligations.
KIN has a Quick Ratio of 7.02. This indicates that KIN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 7.02
Quick Ratio 7.02

More info and screens

3

3. Growth

3.1 Past

KIN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -53.73%.
The Revenue for KIN has decreased by -81.43% in the past year. This is quite bad
EPS 1Y (TTM)-53.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-130.77%
Revenue 1Y (TTM)-81.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-91.06%

3.2 Future

The Earnings Per Share is expected to grow by 12.40% on average over the next years. This is quite good.
Based on estimates for the next years, KIN will show a very strong growth in Revenue. The Revenue will grow by 20.46% on average per year.
EPS Next Y-51.22%
EPS Next 2Y36%
EPS Next 3Y15.8%
EPS Next 5Y12.4%
Revenue Next Year-49.68%
Revenue Next 2Y-1.59%
Revenue Next 3Y3.21%
Revenue Next 5Y20.46%

3.3 Evolution

KIN Yearly Revenue VS EstimatesKIN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
KIN Yearly EPS VS EstimatesKIN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KIN. In the last year negative earnings were reported.
Also next year KIN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KIN Price Earnings VS Forward Price EarningsKIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -10.71
KIN Per share dataKIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as KIN's earnings are expected to grow with 15.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36%
EPS Next 3Y15.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KIN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Kindred Biosciences

NASDAQ:KIN (8/27/2021, 8:19:13 PM)

After market: 9.26 +0.01 (+0.11%)

9.25

+0.01 (+0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)03-15 2022-03-15/amc
Inst Owners0.17%
Inst Owner Change0%
Ins Owners0.51%
Ins Owner Change0%
Market Cap420.52M
Revenue(TTM)7.93M
Net Income(TTM)-41949000
Analysts60
Price Target9.69 (4.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 53.06
P/FCF N/A
P/OCF N/A
P/B 5.27
P/tB N/A
EV/EBITDA -10.71
EPS(TTM)-1.03
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.17
BVpS1.75
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.53%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -500.9%
PM (TTM) -529.26%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.02
Quick Ratio 7.02
Altman-Z 4.83
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-130.77%
EPS Next Y-51.22%
EPS Next 2Y36%
EPS Next 3Y15.8%
EPS Next 5Y12.4%
Revenue 1Y (TTM)-81.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-91.06%
Revenue Next Year-49.68%
Revenue Next 2Y-1.59%
Revenue Next 3Y3.21%
Revenue Next 5Y20.46%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Kindred Biosciences / KIN FAQ

Can you provide the ChartMill fundamental rating for Kindred Biosciences?

ChartMill assigns a fundamental rating of 3 / 10 to KIN.


What is the valuation status of Kindred Biosciences (KIN) stock?

ChartMill assigns a valuation rating of 1 / 10 to Kindred Biosciences (KIN). This can be considered as Overvalued.


What is the profitability of KIN stock?

Kindred Biosciences (KIN) has a profitability rating of 1 / 10.


What is the earnings growth outlook for Kindred Biosciences?

The Earnings per Share (EPS) of Kindred Biosciences (KIN) is expected to decline by -51.22% in the next year.


Can you provide the dividend sustainability for KIN stock?

The dividend rating of Kindred Biosciences (KIN) is 0 / 10 and the dividend payout ratio is 0%.